First anticoagulant approved for preventing VTE recurrence in children

(HealthDay)—Fragmin (dalteparin sodium) injection has been granted the first approval for subcutaneous use in preventing recurrence of symptomatic venous thromboembolism (VTE) in children aged 1 month or older, the U.S. Food and Drug Administration announced. Fragmin has been approved for use in adults since 1994. Approval in children was based on a trial of 38 pediatric patients with symptomatic deep […]

Continue reading »